Study S001893

A Phase III, Randomized, Double-blind, Parallel-group, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Chinese Participants With a BMI >=28 kg/m2 or BMI >=24 kg/m2 With at Least One Weight-related Complication

ClinicalTrials.gov record

Registration

Registration: NCT06214741
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 307
Start: 2024-02-06
Primary completion: 2025-07-29
Lead sponsor: Boehringer Ingelheim
Conditions: Obesity; Overweight
Interventions: DRUG:survodutide; DRUG:Placebo matching BI 456906
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:U1111-1295-9567

Registered primary outcomes

Percentage change in body weight from baseline to Week 52 [At baseline and at Week 52.]
Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 52 [At baseline and at Week 52.]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010930	Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN). Ji L, Diabetes therapy : research, treatment and education of diabetes and related disorders	2026	Randomized trial	PMID 42599381 DOI	cites ClinicalTrials.gov:NCT06214741; registry reference DERIVED:42599381